MilliporeSigma plans to broaden its manufacturing footprint with a combined $47 million investment at its production facilities in Danvers, MA, and Jaffrey, NH. These sites supply products to customers developing a range of therapies, including COVID-19 vaccines, as well as provide products and services for biopharmaceutical manufacturing.
These expansions will significantly increase capacity and output at these facilities in 2021 and 2022, respectively, and create nearly 700 new manufacturing positions, according to the company.
“The global coronavirus pandemic has significantly increased demand for our single-use and virus filtration technologies, which we are supplying to more than 50 different companies working on COVID-19 vaccine candidates,” said Chris Ross, interim CEO, MilliporeSigma. “These investments will strengthen our global manufacturing footprint, allowing us to meet this unprecedented demand and help get lifesaving vaccines and therapies to more patients, faster.”
This expansion will add 65,000 square feet of space to the Danvers single-use assembly operations, adding to the existing 120,000-square-foot facility. The expansion will add the capacity needed to support the manufacturing of products across several portfolios, including Mobius® single-use consumables. The total investment in Danvers is about $25 million and is expected to add approximately 400 jobs throughout 2021.
The Jaffrey expansion plans include adding 25,000 square feet to the existing 260,000-square-foot facility. The additional capacity includes new production lines and equipment to support the manufacturing of filtration devices and membrane products, specifically Durapore® filters, Express® filters, and the Viresolve® product lines. These products are used to ensure the sterility of many lifesaving therapies and to remove viral contamination for a variety of therapies, explained Ross.
The total investment in Jaffrey is about $22 million. This expansion is expected to bring nearly 275 roles by 2022, once the expansion is completed.
